Aditx Therapeutics Inc Stock

$0.09

1.98% today

Nasdaq, Feb 05, 04:21 pm CET

ISIN

US0070251097

Symbol

ADTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Aditx Therapeutics Inc Stock price

$0.10

-404,799.90 100.00% 5Y

Nasdaq, Closing price Tue, Feb 04 2025

-0.01 12.91%

ISIN

US0070251097

Symbol

ADTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$7.56m
Enterprise Value	$17.23m
P/E (TTM) P/E ratio	0.00
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	82.05
P/S ratio (TTM) P/S ratio	36.00
P/B ratio (TTM) P/B ratio	0.01
Revenue growth (TTM) Revenue growth	-71.70%
Revenue (TTM) Revenue	$210.00k
EBIT (operating result TTM) EBIT	$-30.16m
Free Cash Flow (TTM) Free Cash Flow	$-13.92m
Cash position	$330.00k
EPS (TTM) EPS	$-981.65
P/E forward	0.00
P/S forward	1.07
EV/Sales forward	6.31
Short interest	10.42%

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Get Started for Free Today

Aditx Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Aditx Therapeutics Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Aditx Therapeutics Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Aditx Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	0.21 0.21	72% 72% 100%
- Direct Costs	1.43 1.43	18% 18% 681%
Gross Profit	-1.21 -1.21	163% 163% -576%
- Selling and Administrative Expenses	14 14	27% 27% 6,605%
- Research and Development Expense	14 14	148% 148% 6,900%
EBITDA	-30 -30	17% 17% -14,086%
- Depreciation and Amortization	0.58 0.58	2% 2% 276%
EBIT (Operating Income) EBIT	-30 -30	17% 17% -14,364%
Net Profit	-40 -40	36% 36% -19,138%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aditx Therapeutics Inc Stock News

Neutral

Business Wire

●

23 days ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has authorized management to explore taking its subsidiary, Pearsanta, Inc. (“Pearsanta”), public via a proposed initial public offering (“IPO”) in 2025. This decis...

Neutral

Business Wire

●

about 2 months ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. (“Adimune”), has successfully completed all preclinical efficacy and safety studies for its antigen-specific gene therapy, ADI-100. This achievement represents a ma...

Neutral

PRNewsWire

●

3 months ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financia...

More Aditx Therapeutics Inc News

Company Profile

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Head office	United States
CEO	Amro Albanna
Employees	47
Founded	2017
Website	www.aditxt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now